stockrow
Friday 6 November 2026
Export ALC’s income statement to Excel — free account
Alcon
ALC Healthcare Medical Instruments & Supplies
Alcon’s revenue for fiscal 2025 (year ended December 2025) was $10.4 billion, up 4.94% from fiscal 2024.
- Revenue
- +8.74%
- EPS
- −100.0%
- Free cash flow
- −0.54%
- Total debt
- −0.55%
Quarter to June 2026, against a year earlier
74.76
1.79
−2.34%
Follow ALC
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
35.15 | 39.60 | 45.12 | 51.22 |
P/S ratio |
3.61 | 3.74 | 3.45 | 3.01 | |
P/FCF ratio |
26.53 | 24.10 | 23.00 | 20.49 | |
P/Operating CF |
50.76 | 59.07 | 87.82 | 64.03 | |
P/B ratio |
1.66 | 1.76 | 1.66 | 1.51 | |
Price to Tangible BV |
10.04 | 10.30 | 9.18 | 8.03 | |
EV/Sales |
3.93 | 4.04 | 3.74 | 3.31 | |
EV/EBITDA |
15.31 | 16.46 | 15.67 | 13.13 | |
EV/Operating CF |
19.30 | 18.49 | 17.26 | 15.55 | |
EV/FCF |
28.87 | 26.04 | 24.93 | 22.53 | |
Quick Ratio |
1.15 | 1.17 | 1.22 | 1.12 | |
Current Ratio |
2.12 | 2.12 | 2.20 | 2.09 | |
Net Debt/EBITDA |
4.89 | 4.85 | 4.93 | 4.06 | |
Debt/Assets |
15.01% | 15.01% | 14.97% | 15.17% | |
Debt/Equity |
0.21 | 0.22 | 0.21 | 0.22 | |
Asset Turnover |
0.33 | 0.34 | 0.34 | 0.35 | |
Operating CF/Net income |
3.05 | 3.03 | 2.21 | 0.00 | |
Capex/Depreciation |
(0.56) | (0.61) | (0.58) | (0.18) | |
Interest Coverage |
6.51 | 5.91 | 5.62 | 0.21 | |
Research and Development Expense of Revenue |
9.56% | 10.04% | 9.05% | 23.49% | |
Selling, General and Administrative Expense of Revenue |
33.09% | 33.15% | 32.59% | 34.15% | |
Intangible Assets out of Total Assets |
0.58 | 0.58 | 0.57 | 0.56 | |
Share Based Compensation of Revenue |
1.57% | 1.62% | 1.66% | 1.49% | |
Graham Net Nets |
(0.08) | (0.08) | (0.08) | (0.09) | |
Graham Number |
46.22 | 44.73 | 41.32 | 36.16 | |
Earnings Yield |
2.85% | 2.53% | 2.22% | 1.95% | |
Free Cash Flow Yield |
3.77% | 4.15% | 4.35% | 4.88% | |
Revenue per Share |
5.30 | 5.51 | 5.55 | 5.80 | |
Operating CF per Share |
1.47 | 1.33 | 0.86 | 1.05 | |
Capex per Share |
(0.37) | (0.41) | (0.39) | (0.29) | |
Free Cash Flow per Share |
1.09 | 0.93 | 0.47 | 0.76 | |
Cash per Share |
3.04 | 3.26 | 3.41 | 2.99 | |
Shareholders Equity per Share |
44.79 | 44.68 | 45.43 | 44.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
44.79 | 44.68 | 45.43 | 44.37 | |
Free Cash Flow |
540.00 | 457.00 | 227.00 | 370.00 | |
Working Capital |
3,343.00 | 3,400.00 | 3,616.00 | 3,457.00 | |
Capital Expenditures |
(184.00) | (201.00) | (191.00) | (140.00) | |
Net Current Asset Value |
(3,103.00) | (3,071.00) | (2,866.00) | (2,878.00) | |
EV/EBIT |
27.73 | 30.88 | 33.60 | 37.89 | |
Capex to Sales |
0.07 | 0.07 | 0.07 | 0.05 | |
Price to Operating Income |
25.48 | 28.58 | 31.01 | 34.45 | |
| Other line items | |||||
Average Receivables |
1,853.50 | 1,860.50 | 1,933.50 | 2,057.50 | |
Average Payables |
872.00 | 849.50 | 880.50 | 931.50 | |
Average Inventory |
2,405.50 | 2,329.50 | 2,390.50 | 2,452.00 | |
Average Assets |
30,943.00 | 30,951.00 | 31,313.50 | 31,242.50 | |
Average Common Equity |
21,738.50 | 21,794.00 | 22,076.00 | 21,863.00 |
Columns are period end dates